Holen Sie sich die Stockscreener-App
11.65
2.64%
0.30
Handel nachbörslich:
11.07
-0.58
-4.98%
Schlusskurs vom Vortag:
$11.35
Offen:
$11.25
24-Stunden-Volumen:
466.50K
Relative Volume:
0.60
Marktkapitalisierung:
$620.22M
Einnahmen:
$8.78M
Nettoeinkommen (Verlust:
$-104.70M
KGV:
-4.9156
EPS:
-2.37
Netto-Cashflow:
$-82.68M
1W Leistung:
+1.22%
1M Leistung:
+22.12%
6M Leistung:
+5.62%
1J Leistung:
-16.01%
1-Tages-Spanne:
$11.19
$12.00
1-Wochen-Bereich:
$11.17
$12.13
52-Wochen-Spanne:
$5.35
$16.15
Stoke Therapeutics Inc Stock (STOK) Company Profile
Firmenname
Stoke Therapeutics Inc
Sektor
Branche
Telefon
781-430-8200
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Vergleichen Sie STOK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
11.65 | 620.22M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-03-26 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-07-25 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-24 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Eingeleitet | Jefferies | Buy |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-11-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Eingeleitet | UBS | Neutral |
| 2021-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-12-11 | Bestätigt | Needham | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-29 | Eingeleitet | Needham | Buy |
| 2019-12-18 | Eingeleitet | Wedbush | Outperform |
| 2019-11-12 | Eingeleitet | BTIG Research | Buy |
| 2019-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Credit Suisse | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | STOK Stock News - GuruFocus
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
STOK FY2025 EPS Forecast Lowered by Cantor Fitzgerald - Defense World
Stoke Therapeutics: Impressive Pipeline And Big Backers - Seeking Alpha
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Acquired by California State Teachers Retirement System - Defense World
FMR LLC Increases Stake in Stoke Therapeutics Inc: A Strategic M - GuruFocus
Cantor Fitzgerald Comments on STOK FY2026 Earnings - Defense World
Encephalopathy Pipeline 2025: Comprehensive Clinical Trials - openPR.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by Two Sigma Investments LP - Defense World
Ameriprise Financial Inc. Has $116,000 Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Jane Street Group LLC Sells 318,465 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - mx.advfn.com
Millennium Management LLC Increases Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
(STOK) Technical Data - news.stocktradersdaily.com
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Insider Sell: Barry Ticho Sells 8,216 Shares of Stoke Therapeuti - GuruFocus
Insider Sell: Barry Ticho Sells 8,216 Shares of Stoke Therapeutics Inc (STOK) - GuruFocus
Stoke Therapeutics Adopts Key Proposals at Annual Meeting - TipRanks
BNP Paribas Financial Markets Trims Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
ProShare Advisors LLC Acquires Shares of 12,626 Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Contrasting Stoke Therapeutics (NASDAQ:STOK) & Renovaro (NASDAQ:RENB) - Defense World
Stoke Therapeutics to Present at the 2025 Jefferies Global Healthcare Conference - BioSpace
Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference | STOK Stock News - GuruFocus
Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference - Business Wire
D. E. Shaw & Co. Inc. Sells 143,203 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
How to Take Advantage of moves in (STOK) - news.stocktradersdaily.com
Northern Trust Corp Purchases 11,635 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 28% But Its Business Still Trails The Industry - simplywall.st
Chardan Capital Has Strong Forecast for STOK FY2025 Earnings - Defense World
Analysts Issue Forecasts for STOK FY2026 Earnings - Defense World
Research Analysts Issue Forecasts for STOK FY2025 Earnings - Defense World
Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet - MSN
HC Wainwright Analysts Decrease Earnings Estimates for STOK - Defense World
Q2 EPS Estimates for Stoke Therapeutics Raised by Wedbush - Defense World
Stoke Therapeutics (NASDAQ:STOK) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
Stoke Therapeutics stock target cut to $35 by H.C. Wainwright - Investing.com Canada
Price T Rowe Associates Inc. MD Purchases 2,215 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
STOK: HC Wainwright & Co. Maintains Buy Rating on Stoke Therapeu - GuruFocus
Stoke Therapeutics (STOK) Sees Adjusted Price Target Amid Upcoming Trial | STOK Stock News - GuruFocus
Stoke Therapeutics (STOK) Sees Adjusted Price Target Amid Upcomi - GuruFocus
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up After Better-Than-Expected Earnings - Defense World
Stoke Therapeutics Advances with Strong Q1 2025 Results - TipRanks
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates | STOK Stock News - GuruFocus
Stoke Therapeutics (STOK) Reports Significant Q1 Revenue Growth - GuruFocus
Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Stoke Therapeutics Provides Business Updates - citybiz
Stoke Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Stoke Therapeutics Inc (STOK) Reports Q1 2025 Earnings: EPS of $ - GuruFocus
Stoke Therapeutics Q1 Operating Income USD 111.24 Million - marketscreener.com
Stoke Therapeutics Inc (STOK) Reports Q1 2025 Earnings: EPS of $1.90 and Revenue of $158.6 Million, Surpassing Estimates - GuruFocus
Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Stoke Therapeutics Inc-Aktie (STOK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ticho Barry | CHIEF MEDICAL OFFICER |
Jun 03 '25 |
Sale |
10.03 |
6,471 |
64,892 |
25,782 |
| Ticho Barry | CHIEF MEDICAL OFFICER |
Jun 02 '25 |
Sale |
10.00 |
1,745 |
17,450 |
32,253 |
| Ticho Barry | CHIEF MEDICAL OFFICER |
May 02 '25 |
Sale |
10.03 |
22,790 |
228,543 |
33,998 |
| Ticho Barry | CHIEF MEDICAL OFFICER |
May 01 '25 |
Sale |
10.00 |
3,841 |
38,410 |
56,788 |
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):